share_log

康寧傑瑞製藥-B：截至2024年12月31日止年度年度業績公告

ALPHAMAB-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024

HKEX ·  Mar 25 12:16

Summary by Moomoo AI

康寧傑瑞生物製藥於2024財年實現營收人民幣6.40億元，同比增長192.6%；年內實現扭虧為盈，錄得淨利潤1.66億元，而上年同期虧損2.11億元。收入增長主要來自許可費收入大幅增加至4.64億元，以及藥品銷售及特許權使用費收入1.59億元。公司研發投入保持穩定，全年研發支出為4.04億元。期內多個在研產品取得重要進展：KN035獲得CDE突破性療法認定；JSKN003完成多項臨床試驗並獲批開展III期研究；JSKN016及JSKN033的臨床試驗進展順利。公司亦與多家企業達成戰略合作，包括與Glenmark及津曼特等簽署許可協議。截至2024年底，公司現金及現金等價物為11.12億元，較上年增長2.4%。管理層表示將繼續通過獨有的藥物發現及開發能力，為全球患者提供創新治療用生物製劑，並積極尋求更多戰略合作機會，以最大化全球專利資產的商業價值。
康寧傑瑞生物製藥於2024財年實現營收人民幣6.40億元，同比增長192.6%；年內實現扭虧為盈，錄得淨利潤1.66億元，而上年同期虧損2.11億元。收入增長主要來自許可費收入大幅增加至4.64億元，以及藥品銷售及特許權使用費收入1.59億元。公司研發投入保持穩定，全年研發支出為4.04億元。期內多個在研產品取得重要進展：KN035獲得CDE突破性療法認定；JSKN003完成多項臨床試驗並獲批開展III期研究；JSKN016及JSKN033的臨床試驗進展順利。公司亦與多家企業達成戰略合作，包括與Glenmark及津曼特等簽署許可協議。截至2024年底，公司現金及現金等價物為11.12億元，較上年增長2.4%。管理層表示將繼續通過獨有的藥物發現及開發能力，為全球患者提供創新治療用生物製劑，並積極尋求更多戰略合作機會，以最大化全球專利資產的商業價值。
In the fiscal year 2024, Kangning Jiere Biopharmaceutical achieved revenue of RMB 0.64 billion, a year-on-year increase of 192.6%; the company turned a profit during the year, recording a net profit of RMB 0.166 billion, compared to a loss of RMB 0.211 billion in the same period last year. The revenue growth was primarily driven by a significant increase in licensing fee income to RMB 0.464 billion, as well as pharmaceutical sales and royalty income of RMB 0.159 billion.The company's research and development investment remained stable, with annual R&D expenses of RMB 0.404 billion. During the period, several research products made significant progress: KN035 received breakthrough therapy designation from CDE; JSKN003 completed multiple clinical trials and was approved to conduct Phase III studies; and clinical...Show More
In the fiscal year 2024, Kangning Jiere Biopharmaceutical achieved revenue of RMB 0.64 billion, a year-on-year increase of 192.6%; the company turned a profit during the year, recording a net profit of RMB 0.166 billion, compared to a loss of RMB 0.211 billion in the same period last year. The revenue growth was primarily driven by a significant increase in licensing fee income to RMB 0.464 billion, as well as pharmaceutical sales and royalty income of RMB 0.159 billion.The company's research and development investment remained stable, with annual R&D expenses of RMB 0.404 billion. During the period, several research products made significant progress: KN035 received breakthrough therapy designation from CDE; JSKN003 completed multiple clinical trials and was approved to conduct Phase III studies; and clinical trials for JSKN016 and JSKN033 progressed smoothly. The company also reached strategic cooperation agreements with multiple enterprises, including signing licensing agreements with Glenmark and Jinmant.As of the end of 2024, the company's cash and cash equivalents stood at RMB 1.112 billion, an increase of 2.4% from the previous year. Management stated that they would continue to provide innovative therapeutic biologics for global patients through unique drug discovery and development capabilities and actively seek more strategic cooperation opportunities to maximize the commercial value of global patent assets.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 257

Recommended

Related Stocks Related Stocks
Symbol Mini Chart Price
LEPU BIO-B
02157
3.810
MEGA GENOMICS
06667
7.250
MABPHARM-B
02181
0.640
RECBIO-B
02179
8.300
ZAI LAB
09688
30.850
Log In for the Full List
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina Show More
Can strong earnings reports drive Chinese concept stocks to continue rising?
77%
23%
Bullish
Bearish
1532 votes
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
On Tuesday, China's political leadership is convening at the Great Hall of the People in Beijing for the year's most significant event, known as the "Two Sessions." These closed-door meetings are the annual plenary sessions of both the National People's Congress and the Chinese People's Political Consultative Conference, typically held simultaneously in March. The sessions generally last for about ten days....

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
OK